Get started
Author

Doris M Quon

Observed names: D. Quon, DORIS QUON, Doris Quon
OpenAlex ID: A5072718710
A Phase I/II Investigation of Safety and Efficacy of Nivolumab and nab -Sirolimus in Patients With a Variety of Tumors With Genetic Mutations in the mTOR Pathway
2023 · ERLINDA M. GORDON, NICOLE L. ANGEL, et al. · Anticancer Research · 11
PDF
A phase 2 study of talimogene laherparepvec, nivolumab, and trabectedin (TNT) in advanced sarcoma.
2021 · Neal Shiv Chawla, Ted Kim, et al. · Journal of Clinical Oncology · 6
Administration of aldoxorubicin and 14 days continuous infusion of ifosfamide/mesna in metastatic or locally advanced sarcomas.
2017 · Frederick C. Eilber, Kamalesh Kumar Sankhala, et al. · Journal of Clinical Oncology · 6
Phase 1/2 study of safety/efficacy using trabectedin, ipilimumab, and nivolumab as first-line treatment of advanced soft tissue sarcoma (STS).
2018 · Erlinda Maria Gordon, Victoria S. Chua-Alcala, et al. · Journal of Clinical Oncology · 5
The TNT protocol: A phase II study using talimogene laherparepvec (TVEC), nivolumab (N) and trabectedin (T) as first, second/third line therapy for advanced sarcoma, including desmoid tumor and chordoma.
2020 · Sant P. Chawla, Victoria S. Chua, et al. · Journal of Clinical Oncology · 4
The SAINT: Initial results of a phase I/II study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.
2019 · Sant P. Chawla, Victoria S. Chua-Alcala, et al. · Journal of Clinical Oncology · 2
Phase Ib trial of combining aldoxorubicin plus doxorubicin.
2013 · Kamalesh Kumar Sankhala, Sant P. Chawla, et al. · Journal of Clinical Oncology · 2
Phase 1 Study of Bpm 31510 (UBIDECARANONE) in Advanced Solid Tumors: Updated Analysis of a Novel Treatment with Promising Activity
2012 · S.P. Chawla, A. Hendifar, et al. · Annals of Oncology · 2
1739P Linnovate: A phase I/II study of safety/efficacy using lurbinectedin combined with ipilimumab and nivolumab for advanced soft tissue sarcoma (NCT05876715) - Interim analysis of phase I part
2024 · E.M. Gordon, S.P. Chawla, et al. · Annals of Oncology · 1
PDF
Phase I study to evaluate the safety and efficacy of rivoceranib (apatinib) and nivolumab in patients with unresectable or metastatic cancer.
2019 · Sant P. Chawla, Victoria S. Chua, et al. · Journal of Clinical Oncology · 1
First line therapy with aldoxorubicin and 14 days continuous infusion of ifosfamide/mesna in metastatic or locally advanced sarcomas: a phase I-II study
2016 · S.P. Chawla, K. Sankhala, et al. · Annals of Oncology · 1
PDF
Phase I study of BPM 31510 in advanced solid tumors: Updated analysis of a novel treatment with promising activity.
2012 · Andrew Eugene Hendifar, Sant P. Chawla, et al. · Journal of Clinical Oncology · 1
Evaluation of the safety and efficacy of pathotropic nanoparticles bearing a dominant negative cyclin G1 construct for chemoresistant osteosarcoma and other sarcomas: Phase I, II, and III studies
2009 · S. P. Chawla, V. S. Chua, et al. · Journal of Clinical Oncology · 1
2706P Clinical benefit analysis of a phase I/II study using lurbinectedin combined with ipilimumab and nivolumab as first-line therapy for advanced soft tissue sarcoma (NCT05876715)
2025 · S. Jeffrey, A.D. Agarwal, et al. · Annals of Oncology
Abstract CT287: LINNOVATE: A Phase 1/2 study of safety/efficacy using lurbinectedin, combined with ipilimumab, and nivolumab for advanced soft tissue sarcomas (NCT05876715)
2024 · Erlinda M. Gordon, Nadezhda Omelchenko, et al. · Cancer Research
A phase 1b investigation of safety/efficacy of nivolumab and ABI-009 (nab-rapamycin) in advanced undifferentiated pleomorphic sarcoma (UPS), liposarcoma (LPS), chondrosarcoma (CS), osteosarcoma (OS) and Ewing sarcoma.
2018 · Erlinda Maria Gordon, Victoria S. Chua-Alcala, et al. · Journal of Clinical Oncology
INNO-206 is an Active Drug for Relapsed Advanced Soft Tissue Sarcoma
2012 · S. Chawla, V.S. Chua, et al. · Annals of Oncology
PDF
Works count: 17
Citation count: 43
H-index: 4
I10-index: 1
Year
Topic
Type